Managing Seasonal Allergies
(Modified May 2023)
The management of seasonal allergies includes nonpharmacologic and pharmacologic approaches.1 Nonpharmacologic measures include nasal irrigation and allergen avoidance (e.g., keeping windows closed, using window screen filters and air conditioning, limiting outdoor time during peak allergen season, showering after outdoor exposure).3 Choose a medication based on severity of symptoms, patient age, other medical conditions, and preferences.2 Immunotherapy (subcutaneous or sublingual) can be considered if other management is not adequate or if the patient has seasonal allergies in combination with asthma.1,2 Alternative therapies (e.g., supplements, homeopathy, and acupuncture) have been used and promoted for seasonal allergies; however, there are insufficient data to recommend these therapies.3,4
Drug/Class |
Consider for… |
Avoid or use particular caution… |
Nasal corticosteroids See a comparison of nasal sprays for allergic rhinitis later in the document. |
First-line for moderate to severe, persistent symptoms.3,5 Nasal congestion.3,5 Itchy, irritated, or watery eyes.3 |
Children:9,14
|
Oral antihistamines See our comparison of first- and second-generation antihistamines at the end of this document. |
First-line for mild or intermittent symptoms (second generation).3,5 Itching, sneezing, rhinorrhea (second generation).5 |
Under two years (most second generation).9,22
Elderly, risk of excessive sedation (first generation, cetirizine).9 Risk for decreased cognition or motor skills (first generation).9 Glaucoma (first generation).9 Severe liver impairment.9 Severe kidney impairment (cetirizine, desloratadine, rupatadine [Canada]).9,24 With moderate or strong CYP3A4 inhibitors, grapefruit juice (rupatadine [Canada]).24 With orange, grapefruit, or apple juice; other OATP inhibitors (fexofenadine).7 Prolonged QT interval (Canada: bilastine, rupatadine).24,25 |
Nasal antihistamines See a comparison of nasal sprays for allergic rhinitis later in the document. |
Add-on therapy with nasal steroids, if needed (especially for nasal congestion).1,3,8 |
Under two years (Astepro [US]) or under five years (Astelin [US]).9 Under six years (olopatadine).9 Neither available as single-ingredient nasal sprays in Canada. |
Ophthalmic antihistamines |
Add-on therapy for eye symptoms with nasal steroids, if needed.1 |
Under three years (ketotifen, olopatadine [Canada]).9,15,16 Under two years (olopatadine [US]).9 |
Decongestants (intranasal, oral) |
Inadequate response from a nasal steroid for nasal congestion.2 Use in combination with an oral antihistamine (intranasal).3 Intermittent nasal congestion.2 |
Hypertension, arrhythmia, coronary heart disease, hyperthyroidism, glaucoma, diabetes, and benign prostatic hypertrophy (oral).2 Prolonged use (more than three to five days) (intranasal).2,3 With monoamine oxidase inhibitors.6 Monotherapy (intranasal).6 |
Cromolyn (intranasal [US]) See a comparison of nasal sprays for allergic rhinitis later in the document. |
Prevention. Inadequate response with other treatments. Children when parents have safety concerns with other therapy.6 |
Under two years.9 |
Leukotriene receptor antagonists (montelukast) |
Use as a last resort.6,10 Use if coexisting asthma.1 |
For seasonal allergic rhinitis: under two years (US), under 15 years (Canada).17,18 Anxiety, depression, and psychiatric disorders.6 |
Oral corticosteroids |
Use as a last resort for severe symptoms.6,20,21 |
Prolonged use (more than a few days).6,20,21 |
Comparison of Nasal Sprays for Allergic Rhinitis
Product |
Adult Dosea |
Pediatric Dosea |
Generic available? |
Costb |
Azelastine 0.1% |
1 to 2 sprays |
5 to 11 years: |
Yes |
(200 sprays) |
Azelastine 0.15% |
1 to 2 sprays in each nostril BID |
6 to 11 years: |
No |
(120 sprays) |
Azelastine 0.15% |
Seasonal allergies:
Perennial allergies: |
6 to 11 years: |
Yes |
(200 sprays) |
Azelastine/Fluticasone |
(fluticasone: 50 mcg/spray) |
(fluticasone: 50 mcg/spray) |
Yes |
(120 sprays) |
Beclomethasone |
(50 mcg/spray) |
(50 mcg/spray) |
Yes |
(200 sprays) |
Beclomethasone |
(42 mcg/spray) |
(42 mcg/spray) |
No |
(180 sprays) |
Beclomethasone |
(80 mcg/spray): |
(40 mcg/spray): |
No |
(80 mcg; 120 sprays) |
Budesonide |
US (32 mcg/spray): |
US (32 mcg/spray) |
No |
(120 sprays) |
Canada (64 mcg/spray): |
Canada (64 mcg/spray): |
Yes |
(64 mcg; 165 sprays) |
|
Budesonide |
(32 mcg/spray) |
(32 mcg/spray) |
Yes |
(120 sprays) |
Ciclesonide |
(50 mcg/spray) |
(50 mcg/spray) |
No |
(120 sprays) |
Ciclesonide |
(37 mcg/spray) |
Not indicated for patients under 12 years. |
No |
(60 sprays) |
Cromolyn |
1 spray in each nostril |
2 to 11 years: |
Yes |
(200 sprays) |
Flunisolide |
(50 mcg/spray) |
(50 mcg/spray) |
Yes |
(200 sprays) |
Fluticasone furoate |
(27.5 mcg/spray) |
(27.5 mcg/spray) |
No |
(60 sprays) |
Fluticasone furoate |
(27.5 mcg/spray) |
(27.5 mcg/spray) |
No |
(120 sprays) |
Fluticasone propionate |
(50 mcg/spray) |
(50 mcg/spray) |
Yes |
(144 sprays) |
Fluticasone propionate |
Not indicated for patients over the age of 18 years. |
(50 mcg/spray) |
Yes |
(60 sprays) |
Ipratropium |
(21 mcg/spray) |
(21 mcg/spray) |
Yes |
(345 sprays) |
Ipratropium |
2 sprays in each nostril four times daily |
5 to 12 years: |
Yes |
(165 sprays) |
Mometasone |
(50 mcg/spray) |
(50 mcg/spray) |
No |
(60 sprays) |
Mometasonef |
(50 mcg/spray) |
(50 mcg/spray) |
Yes |
(120 sprays) |
Olopatadine |
2 sprays in each nostril BID |
6 to 11 years: |
Yes |
(240 sprays) |
Olopatadine/Mometasone |
(mometasone: 25 mcg/spray) |
(mometasone: 25 mcg/spray) 6 to 11 years (Canada): |
No |
(240 sprays) |
Triamcinolone |
Not indicated for patients older than 12 years |
(55 mcg/spray) |
Yes |
(120 sprays) |
Triamcinolone |
(55 mcg/spray) |
(55 mcg/spray) |
Yes |
(60 sprays) |
Abbreviations: AH = antihistamine; ACH = anticholinergic; BID = twice daily; MCS = mast cell stabilizer; OTC = over-the-counter; QID = four times daily; Rx = prescription; S = steroid; TID = three times daily.
- Dosing per FDA- or Health Canada-approved product labeling.* If pediatric dose is 1 to 2 sprays, start with 1 spray.
- Pricing based on wholesale acquisition cost (WAC), for generic product if available. US medication pricing by Elsevier, accessed March 2023. (Astepro, Nasonex 24 Allergy, and Flonase Allergy Relief pricing obtained from internet retailer pricing [e.g., Amazon.com], accessed March 2023).
- Indicated for seasonal allergic rhinitis only.
- Indicated for perennial allergic rhinitis only.
- Note that Rx Flonase (US) (fluticasone propionate, available only as generics) is indicated for perennial nonallergic rhinitis.
- Aqueous formulation.
- Alcohol-based formulation.
- Canadian product is available; however, not included within this chart as it is only indicated for rhinorrhea associated with the common cold.
*The following US product labeling was used for the above chart: Azelastine 0.1% (March 2021), Astepro Allergy (OTC labeling accessed March 15, 2023), Azelastine 0.15% (December 2021), Dymista (August 2022), Beconase AQ (February 2021), Qnasl (Teva September 2022), Rhinocort Aqua (February 2012), Rhinocort Allergy (January 2022), Omnaris (May 2019), Zetonna (February 2023), NasalCrom (February 2022), Flunisolide (May 2019), Flonase Sensimist (January 2023), Flonase Allergy Relief (December 2022), Ipratropium 0.03% (July 2022), Ipratropium 0.06% (July 2022), Nasonex 24HR Allergy (OTC labeling accessed March 15, 2023), Mometasone (Apotex; July 2018), Patanase (June 2021), Ryaltris (October 2022), Nasacort Allergy 24HR (OTC labeling accessed March 15, 2023). The following Canadian product labeling was used for the above chart: Dymista (May 2022); Apo-beclomethasone (March 2021); Rhinocort Aqua 64 mcg/spray (August 2019); Mylan-budesonide AQ 100 mcg/spray (May 2020); Omnaris (February 2021); Avamys (December 2021); Flonase (May 2020); pms-ipratropium (October 2012); Nasonex (March 2022); Ryaltris (September 2022); Nasacort AQ (September 2022).
Comparison of First- and Second-Generation Antihistamines
Second-generation antihistamines are often recommended over first-generation antihistamines as they are as effective and have less sedation or other adverse effects.11-13,19
First-Generation Antihistamines11-13,19 |
Second-Generation Antihistamines11-13,19 |
Some examples of first-generation antihistamines include:
Non-selective (target histamine-1 receptors, but also cholinergic, alpha-adrenergic, and serotonergic receptors). Can have substantial adverse effects, especially in older patients (not recommended in patients >65 years old). Most common adverse effect is sedation. May decrease cognitive and motor skills, use with caution. Some (especially children) may have stimulating effects (e.g., insomnia, anxiety, hallucinations). Can cause anticholinergic effects (e.g., dry mouth, dry eyes, constipation, tachycardia). |
Some examples of second-generation antihistamines include:
Selective (more specific to peripheral histamine-1 receptors; don’t cross the blood-brain barrier). Generally well tolerated. Generally not sedating (note that cetirizine may be slightly more sedating than others). Can be more expensive than first-generation antihistamines. |
References
- Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis: An evidence-based focused 2017 guideline update. Ann Allergy Asthma Immunol. 2017 Dec;119(6):489-511.
- Sur DK, Plesa ML. Treatment of Allergic Rhinitis. Am Fam Physician. 2015 Dec 1;92(11):985-92.
- Small P, Keith PK, Kim H. Allergic rhinitis. Allergy Asthma Clin Immunol. 2018 Sep 12;14(Suppl 2):51.
- Brinkhaus B, Ortiz M, Witt CM, et al. Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Ann Intern Med. 2013 Feb 19;158(4):225-34.
- Seidman MD, Gurgel RK, Lin SY, et al. Clinical practice guideline: Allergic rhinitis. Otolaryngol Head Neck Surg. 2015 Feb;152(1 Suppl):S1-43.
- deShazo RD, Kemp SF. Pharmacotherapy of allergic rhinitis. Last updated August 17, 2022. In UpToDate, Post TW (ed), UpToDate, Waltham, MA 02013.
- Bailey DG. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55.
- Wallace DV, Dykewicz MS, Oppenheimer J, et al. Pharmacologic Treatment of Seasonal Allergic Rhinitis: Synopsis of Guidance From the 2017 Joint Task Force on Practice Parameters. Ann Intern Med. 2017 Dec 19;167(12):876-881. Erratum in: Ann Intern Med. 2018 May 15;168(10):756.
- Clinical Pharmacology powered by ClinicalKey. Tampa (FL): Elsevier. 2023. http://www.clinicalkey.com. (Accessed March 14, 2023).
- FDA. FDA requires boxed warnings about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. March 4, 2020. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug. (Accessed March 14, 2023).
- Fein MN, Fischer DA, O'Keefe AW, Sussman GL. CSACI position statement: Newer generation H1-antihistamines are safer than first-generation H1-antihistamines and should be the first-line antihistamines for the treatment of allergic rhinitis and urticaria. Allergy Asthma Clin Immunol. 2019 Oct 1;15:61.
- Church MK, Church DS. Pharmacology of antihistamines. Indian J Dermatol. 2013 May;58(3):219-24.
- Wang XY, Lim-Jurado M, Prepageran N, et al. Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine. Ther Clin Risk Manag. 2016 Apr 13;12:585-97.
- eCPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2023. Corticosteroids: eye, ear, nose. September 1, 2018. http://www.e-therapeutics.ca. (Accessed March 14, 2023).
- Product monograph for Zaditor. Aurium Pharma. Concord, ON L4K 4X3. February 2012.
- Product monograph for Patanol. Novartis. Dorval, QC H9S 1A9. March 2018.
- Product information for Singulair. Organon. Jersey City, NJ 07032. February 2021.
- Product monograph for Singulair. Organon Canada. Kirkland, QC H9H 4M7. May 2021.
- American Academy of Family Physicians. Clinical practice guideline: allergic rhinitis. Reaffirmed April 2020. https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/allergic-rhinitis.html. (Accessed March 14, 2023).
- Hox V, Lourijsen E, Jordens A, et al. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl Allergy. 2020 Jan 3;10:1. Erratum in: Clin Transl Allergy. 2020 Sep 28;10:38.
- May JR, Dolen WK. Management of allergic rhinitis: a review for the community pharmacist. Clinical Therapeutics. November 2017. https://www.clinicaltherapeutics.com/article/S0149-2918(17)31006-8/pdf. (Accessed March 14, 2023).
- Chu DK, Oykhman P, Sussman GL. How to use antihistamines. CMAJ. 2021 Apr 6;193(14):E478-E479.
- Product monograph for Allegra. Sanofi Consumer Health. Laval QC H7V 0A3. October 2021.
- Product monograph for Rupall. Medexus. Bolton ON L7E1K1. January 2023.
- Product monograph for Blexten. Aralez Pharmaceuticals Canada. Mississauga ON L5N 6J5. August 2021.
Cite this document as follows: Clinical Resource, Managing Seasonal Allergies. Pharmacist’s Letter/Pharmacy Technician’s Letter/Prescriber’s Letter. April 2023. [390433]